ALXO vs. ZNTL, ETNB, PRAX, OPK, ARQT, SPRY, EOLS, ABVX, OCUL, and TNGX
Should you be buying ALX Oncology stock or one of its competitors? The main competitors of ALX Oncology include Zentalis Pharmaceuticals (ZNTL), 89bio (ETNB), Praxis Precision Medicines (PRAX), OPKO Health (OPK), Arcutis Biotherapeutics (ARQT), ARS Pharmaceuticals (SPRY), Evolus (EOLS), ABIVAX Société Anonyme (ABVX), Ocular Therapeutix (OCUL), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical preparations" industry.
Zentalis Pharmaceuticals (NASDAQ:ZNTL) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.
In the previous week, Zentalis Pharmaceuticals had 22 more articles in the media than ALX Oncology. MarketBeat recorded 35 mentions for Zentalis Pharmaceuticals and 13 mentions for ALX Oncology. Zentalis Pharmaceuticals' average media sentiment score of 0.75 beat ALX Oncology's score of 0.49 indicating that ALX Oncology is being referred to more favorably in the news media.
ALX Oncology is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
98.0% of ALX Oncology shares are held by institutional investors. 6.1% of Zentalis Pharmaceuticals shares are held by company insiders. Comparatively, 33.4% of ALX Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
ALX Oncology's return on equity of -46.05% beat Zentalis Pharmaceuticals' return on equity.
Zentalis Pharmaceuticals has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.
Zentalis Pharmaceuticals presently has a consensus price target of $37.14, suggesting a potential upside of 211.86%. ALX Oncology has a consensus price target of $18.83, suggesting a potential upside of 18.45%. Given ALX Oncology's higher probable upside, equities research analysts clearly believe Zentalis Pharmaceuticals is more favorable than ALX Oncology.
Zentalis Pharmaceuticals received 12 more outperform votes than ALX Oncology when rated by MarketBeat users. Likewise, 65.00% of users gave Zentalis Pharmaceuticals an outperform vote while only 61.54% of users gave ALX Oncology an outperform vote.
Summary
Zentalis Pharmaceuticals beats ALX Oncology on 9 of the 15 factors compared between the two stocks.
Get ALX Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ALX Oncology Competitors List
Related Companies and Tools
